暗記メーカー

暗記メーカー

​
ログイン
GENERAL PRINCIPLES
72問 • 1年前
  • Tameyra Stefani Al-Suhairy
    • 通報

    問題一覧

  • 1

    Complimentary medicine

  • 2

    Botanicals (herbs & plant extracts)

    Alternative health care

  • 3

    Pharmacokinetics

  • 4

    Absorption

  • 5

    Absorption

  • 6

    Absorption

  • 7

    Distribution

  • 8

    Distribution

  • 9

    Metabolism

  • 10

    Phase l metabolism

  • 11

    Phase 2 metabolism

  • 12

    Kidneys renal disease adjust urine pH to accelerate excretion of the drug

    Elimination

  • 13

    3 Basic parameters of pharmacokinetics:

    Volume of distribution, Clearance, t ½ or drug half-life

  • 14

    Bioavailability

  • 15

    Immediate effects

  • 16

    Delayed effects

  • 17

    Cumulative effects

  • 18

    Loading dose

  • 19

    Maintenance dose

  • 20

    Intermittent dose:

  • 21

    Pharmacodynamic

  • 22

    Pharmacodynamics

  • 23

    Full agonist

  • 24

    Partial agonist

  • 25

    Neutral antagonist

  • 26

    Inverse agonist

  • 27

    spare receptors

  • 28

    Full agonist

  • 29

    Partial agonists

  • 30

    competitive antagonist

  • 31

    irreversible

  • 32

    physiologic

  • 33

    Tolerance

  • 34

    Tachyphylaxis

  • 35

    Pharmaceutical equivalent

  • 36

    Therapeutic equivalent

  • 37

    Pharmacokinetic

  • 38

    Pharmacodynamic

  • 39

    Displacement

  • 40

    Interference

  • 41

    Additive

  • 42

    Synergism

  • 43

    Antagonism

  • 44

    Pharmacogenomics

  • 45

    Adverse Drug Reaction

  • 46

    Adverse Drug Reaction:

  • 47

    subject bias

  • 48

    Double blind both subject and evaluator

    observer bias

  • 49

    Case report/case series

  • 50

    Cohort

  • 51

    Case control

  • 52

    Meta analysis

  • 53

    Controlled trials (randomized)

  • 54

    Graded dose response

  • 55

    Quantal dose effect response

  • 56

    growth hormone erythropoietin interferon

    cytokine receptor

  • 57

    hypnotic sedative anticonvulsant

    Ligand-gated channels

  • 58

    insulin growth factor

    Ligand regulated transmembrane enzymes

  • 59

    NO hormones corticosteroids sex hormones vit D thyroid hormone

    Intracellular receptors for lipid soluble agents

  • 60

    opioid analgesic antibiotics

    G-proteins and 2nd messengers

  • 61

    dimecaprol heavy metals

    chemical

  • 62

    Which is NOT a parameter of pharmacodynamics?

    clearance

  • 63

    This phase of clinical drug evaluation utilizes both healthy subjects as well as those with the disease, in order to determine if the drug works double blind

    not sure

  • 64

    The branch of pharmacology that studies the use of drugs in the diagnosis, treatment and prevention of diseases

    Pharmacotherapeutics

  • 65

    Which is a factor that can affect drug absorption

    drug solubility

  • 66

    If a drug has a long half-life, it means

    The drug is eliminated slower from the body.

  • 67

    An INCORRECT statement about the oral route of drug administration:

    It avoids 1st pass metabolism.

  • 68

    This process of pharmacokinetics refers to making a drug more polar thru biotransformation in order for the drug to be eventually eliminated in the kidneys

    metabolism

  • 69

    drug INDUCER means that a drug

    When combined with another may decrease its' bioavailability

  • 70

    The apparent space in the body that is able to contain a drug refers to a drug's

    Volume of distribution

  • 71

    A drug AGONIST is described as:

    A drug that binds with a receptor to produce an effect

  • 72

    This refers to the margin of safety of a drug, and is measured by a drugs' toxic dose over a drugs' effective dose:

    Therapeutic index

    • Sporeformers

    Sporeformers

    Tameyra Stefani Al-Suhairy · 44問 · 1年前

    Sporeformers

    Sporeformers

    44問 • 1年前
    Tameyra Stefani Al-Suhairy

    Spirochetes

    Spirochetes

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Spirochetes

    Spirochetes

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Subcutaneous, Systemic, Opportunistic Mycoses

    Subcutaneous, Systemic, Opportunistic Mycoses

    Tameyra Stefani Al-Suhairy · 75問 · 1年前

    Subcutaneous, Systemic, Opportunistic Mycoses

    Subcutaneous, Systemic, Opportunistic Mycoses

    75問 • 1年前
    Tameyra Stefani Al-Suhairy

    Mycobacteria

    Mycobacteria

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Mycobacteria

    Mycobacteria

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Bacterial Classification, morphology, utrastructure

    Bacterial Classification, morphology, utrastructure

    Tameyra Stefani Al-Suhairy · 64問 · 1年前

    Bacterial Classification, morphology, utrastructure

    Bacterial Classification, morphology, utrastructure

    64問 • 1年前
    Tameyra Stefani Al-Suhairy

    HIV

    HIV

    Tameyra Stefani Al-Suhairy · 31問 · 1年前

    HIV

    HIV

    31問 • 1年前
    Tameyra Stefani Al-Suhairy

    CORONA

    CORONA

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    CORONA

    CORONA

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    PAPILLO

    PAPILLO

    Tameyra Stefani Al-Suhairy · 15問 · 1年前

    PAPILLO

    PAPILLO

    15問 • 1年前
    Tameyra Stefani Al-Suhairy

    ADENO

    ADENO

    Tameyra Stefani Al-Suhairy · 16問 · 1年前

    ADENO

    ADENO

    16問 • 1年前
    Tameyra Stefani Al-Suhairy

    POX

    POX

    Tameyra Stefani Al-Suhairy · 6問 · 1年前

    POX

    POX

    6問 • 1年前
    Tameyra Stefani Al-Suhairy

    PARVO

    PARVO

    Tameyra Stefani Al-Suhairy · 25問 · 1年前

    PARVO

    PARVO

    25問 • 1年前
    Tameyra Stefani Al-Suhairy

    HEPATOTROPHIC

    HEPATOTROPHIC

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    HEPATOTROPHIC

    HEPATOTROPHIC

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    PICORNA

    PICORNA

    Tameyra Stefani Al-Suhairy · 25問 · 1年前

    PICORNA

    PICORNA

    25問 • 1年前
    Tameyra Stefani Al-Suhairy

    RABIES

    RABIES

    Tameyra Stefani Al-Suhairy · 26問 · 1年前

    RABIES

    RABIES

    26問 • 1年前
    Tameyra Stefani Al-Suhairy

    PARAMYXO

    PARAMYXO

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    PARAMYXO

    PARAMYXO

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    HERPES

    HERPES

    Tameyra Stefani Al-Suhairy · 40問 · 1年前

    HERPES

    HERPES

    40問 • 1年前
    Tameyra Stefani Al-Suhairy

    ORTHO

    ORTHO

    Tameyra Stefani Al-Suhairy · 7問 · 1年前

    ORTHO

    ORTHO

    7問 • 1年前
    Tameyra Stefani Al-Suhairy

    FLAVI

    FLAVI

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    FLAVI

    FLAVI

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    TOGA

    TOGA

    Tameyra Stefani Al-Suhairy · 19問 · 1年前

    TOGA

    TOGA

    19問 • 1年前
    Tameyra Stefani Al-Suhairy

    VIRUS STRUCTURE

    VIRUS STRUCTURE

    Tameyra Stefani Al-Suhairy · 16問 · 1年前

    VIRUS STRUCTURE

    VIRUS STRUCTURE

    16問 • 1年前
    Tameyra Stefani Al-Suhairy

    問題一覧

  • 1

    Complimentary medicine

  • 2

    Botanicals (herbs & plant extracts)

    Alternative health care

  • 3

    Pharmacokinetics

  • 4

    Absorption

  • 5

    Absorption

  • 6

    Absorption

  • 7

    Distribution

  • 8

    Distribution

  • 9

    Metabolism

  • 10

    Phase l metabolism

  • 11

    Phase 2 metabolism

  • 12

    Kidneys renal disease adjust urine pH to accelerate excretion of the drug

    Elimination

  • 13

    3 Basic parameters of pharmacokinetics:

    Volume of distribution, Clearance, t ½ or drug half-life

  • 14

    Bioavailability

  • 15

    Immediate effects

  • 16

    Delayed effects

  • 17

    Cumulative effects

  • 18

    Loading dose

  • 19

    Maintenance dose

  • 20

    Intermittent dose:

  • 21

    Pharmacodynamic

  • 22

    Pharmacodynamics

  • 23

    Full agonist

  • 24

    Partial agonist

  • 25

    Neutral antagonist

  • 26

    Inverse agonist

  • 27

    spare receptors

  • 28

    Full agonist

  • 29

    Partial agonists

  • 30

    competitive antagonist

  • 31

    irreversible

  • 32

    physiologic

  • 33

    Tolerance

  • 34

    Tachyphylaxis

  • 35

    Pharmaceutical equivalent

  • 36

    Therapeutic equivalent

  • 37

    Pharmacokinetic

  • 38

    Pharmacodynamic

  • 39

    Displacement

  • 40

    Interference

  • 41

    Additive

  • 42

    Synergism

  • 43

    Antagonism

  • 44

    Pharmacogenomics

  • 45

    Adverse Drug Reaction

  • 46

    Adverse Drug Reaction:

  • 47

    subject bias

  • 48

    Double blind both subject and evaluator

    observer bias

  • 49

    Case report/case series

  • 50

    Cohort

  • 51

    Case control

  • 52

    Meta analysis

  • 53

    Controlled trials (randomized)

  • 54

    Graded dose response

  • 55

    Quantal dose effect response

  • 56

    growth hormone erythropoietin interferon

    cytokine receptor

  • 57

    hypnotic sedative anticonvulsant

    Ligand-gated channels

  • 58

    insulin growth factor

    Ligand regulated transmembrane enzymes

  • 59

    NO hormones corticosteroids sex hormones vit D thyroid hormone

    Intracellular receptors for lipid soluble agents

  • 60

    opioid analgesic antibiotics

    G-proteins and 2nd messengers

  • 61

    dimecaprol heavy metals

    chemical

  • 62

    Which is NOT a parameter of pharmacodynamics?

    clearance

  • 63

    This phase of clinical drug evaluation utilizes both healthy subjects as well as those with the disease, in order to determine if the drug works double blind

    not sure

  • 64

    The branch of pharmacology that studies the use of drugs in the diagnosis, treatment and prevention of diseases

    Pharmacotherapeutics

  • 65

    Which is a factor that can affect drug absorption

    drug solubility

  • 66

    If a drug has a long half-life, it means

    The drug is eliminated slower from the body.

  • 67

    An INCORRECT statement about the oral route of drug administration:

    It avoids 1st pass metabolism.

  • 68

    This process of pharmacokinetics refers to making a drug more polar thru biotransformation in order for the drug to be eventually eliminated in the kidneys

    metabolism

  • 69

    drug INDUCER means that a drug

    When combined with another may decrease its' bioavailability

  • 70

    The apparent space in the body that is able to contain a drug refers to a drug's

    Volume of distribution

  • 71

    A drug AGONIST is described as:

    A drug that binds with a receptor to produce an effect

  • 72

    This refers to the margin of safety of a drug, and is measured by a drugs' toxic dose over a drugs' effective dose:

    Therapeutic index